Honigman Advises Elucid Bioimaging Inc. on $80 Million Series C Funding Round
Honigman represented Elucid Bioimaging Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, on an $80 million Series C financing round. The round was led by Elevage Medical Technologies, with additional participation from industry strategics and existing investors. With this funding, Elucid is poised to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease. This round brings the company’s total funding to $121 million.
The Honigman team was led by corporate partners Phil Torrence and John Hertel.
Honigman LLP is an Am Law 200 full-service, general business law firm with more than 350 attorneys in Chicago, Michigan (Ann Arbor, Bloomfield Hills, Detroit, Grand Rapids, Kalamazoo and Lansing), Washington, D.C. and its newest office in Israel (through its wholly owned subsidiary, Honigman Law Israel). Honigman lawyers counsel clients on complex issues in more than 60 areas of law. For more information, visit www.honigman.com.